

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb

August 06, 2013

LAVAL, Quebec, Aug. 6, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Bausch + Lomb Holdings Incorporated. Bausch + Lomb is a leading global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands *Besivance*, *Lotemax*, *Ocuvite* and *PreserVision*; vision care brands *Biotrue ONEday*, *PureVision*, *renu* and *Boston*; and surgical brands *enVista*, *Storz*, *Stellaris* and *VICTUS*.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.